Treatment-resistant depression: treatment options and next steps

A practical definition

The term describes response—not worth, effort, or hope.

Depression may be called treatment-resistant when it has not improved enough after appropriate treatment attempts, but the exact definition can vary by clinical setting, guideline, study, insurer, and proposed next treatment.

The label should prompt questions, not shortcuts. Was the diagnosis correct? Were medications taken at a useful dose and duration? Was psychotherapy available and matched to the situation? Did side effects limit treatment? Are bipolar symptoms, substance use, sleep disorders, medical illness, trauma, or social conditions changing the picture? Those questions affect what “not working” actually means.

Why the designation matters

After two well-documented medication trials, the odds and the decision change.

Treatment resistance is clinically useful when it documents that appropriate care has not produced enough improvement. It tells the care team to verify the diagnosis and earlier trials, then widen the discussion beyond repeatedly trying similar medication strategies.

The NIMH-funded STAR*D study followed people through sequential medication steps and measured remission, meaning minimal or no depressive symptoms. Roughly one-third reached remission during the first medication step. Among people who continued, about one-quarter reached remission at the second step, approximately 12% to 20% at the third step, and about 7% to 10% at the fourth step. These are study-level remission results—not a prediction for one person—but they show why a careful reassessment and a broader set of options matter as unsuccessful treatment attempts accumulate.

Tolerability matters alongside symptom response. Weight change, sexual side effects, sleep disruption, emotional blunting, or other adverse effects may make an otherwise reasonable medication difficult to continue. A clinician should document both benefit and burden rather than recording every stopped medication as a simple “failure.”

STAR*D reported remission and response in different ways at different treatment levels. This page uses NIMH's remission summaries so the percentages are not mixed or presented as personal odds.

Evidence, labeling, and safeguards

FDA status tells you what was reviewed—and what still needs to be asked.

For a medication, FDA approval connects a specific product and indication to reviewed evidence, dosing, warnings, contraindications, manufacturing standards, and labeling. For a medical device such as TMS, the precise term is generally FDA cleared, and the device and protocol still need to match the patient and the authorized indication.

FDA status does not mean a treatment is risk-free, guaranteed to work, or automatically covered by insurance. It does help patients and clinicians distinguish an authorized use from an off-label or investigational pathway. Insurers may consider FDA status, diagnosis, prior-treatment documentation, network rules, and authorization criteria when deciding coverage, so the clinical decision and the benefit decision should be verified separately.

SPRAVATO (esketamine) is FDA-approved for treatment-resistant depression in adults as monotherapy or with an oral antidepressant under its current label. TMS devices are FDA-cleared for defined indications and protocols. Ketamine products are FDA-approved as anesthetics, but ketamine is not FDA-approved for a psychiatric indication; psychiatric use is off label.

Before choosing a device or medication

A structured reassessment can change the next step.

A careful review should bring the diagnosis, safety, treatment history, medical contributors, daily function, and patient goals into one plan.

Different pathways in plain language

TMS changes circuit activity; esketamine acts through glutamate signaling.

A mechanism can help explain why treatments differ, but it cannot predict an individual response or replace diagnosis, safety screening, and informed consent.

Research is not the same as approval

Psilocybin, LSD, and MDMA remain investigational—not established depression treatments.

The FDA has issued guidance for clinical research involving psychedelic drugs, including psilocybin, LSD, and MDMA. That research interest does not mean these drugs are FDA-approved for depression or appropriate for self-treatment.

Clinical trials must answer questions about dose, psychological support, expectancy effects, durability, abuse potential, cardiovascular and psychiatric risks, and who should not receive treatment. Patients who want to explore an investigational option should discuss registered clinical trials with a qualified clinician and verify the study through ClinicalTrials.gov rather than relying on unregulated treatment claims.

A decision map, not a prescription

Treatment for treatment-resistant depression starts with reassessment—not a single product.

A clinician may revisit diagnosis, safety, prior medication trials, psychotherapy, medical contributors, and daily function before discussing changes to standard care or an advanced treatment.

Leading clinical guidance treats advanced care as a sequence of decisions. The appropriate option depends on the diagnosis, severity, urgency, earlier response and side effects, co-occurring conditions, patient preference, treatment setting, and access. The categories below are conversation starters—not instructions to start, stop, or change treatment on your own.

This framework is consistent with the VA/DoD major-depression guideline's advanced-care approach and NIMH resources on sequential treatment and brain-stimulation therapies.

Advanced care is not one treatment

Compare what changes, where treatment happens, and which safety questions matter.

Depending on diagnosis, severity, prior care, safety, preference, and access, the conversation may include medication changes, evidence-based psychotherapy, TMS, SPRAVATO/esketamine, ECT, ketamine used off label, or a different level of care.

Make the next visit more useful

Bring the treatment story—not just a list of what “failed.”

A concise timeline of diagnoses, medications, psychotherapy, hospital care, advanced treatments, benefit, side effects, and reasons for stopping gives a specialist a stronger starting point.

• Write each medication name, highest remembered dose, approximate duration, benefit, side effects, and why it stopped.
• List therapy types, frequency, duration, and what helped or did not fit.
• Note major sleep, substance-use, medical, hormonal, pain, or neurologic concerns.
• Ask how the clinician confirms diagnosis and measures progress.
• Ask what urgent changes require a call, crisis support, emergency care, or a higher level of treatment.

Keep this private history with your treating team. Advanced Depression Care does not ask you to submit it through the public website.